Nautilus Biotechnology, Inc. (NAUT) News
Follow Nautilus Biotechnology, Inc. (NAUT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Nautilus Biotechnology Q3 revenue beats
EQUITY | Oct 27, 2026, 10:12 AM UTC
M
Nautilus Biotechnology Reports Q3 2026 Net Loss of $15.6M
The company reported Q3 2026 revenue of $0.2M, operating expenses of $16.9M and cash, cash equivalents and investments of $114.3M as of Sept. 30, 2026.
EQUITY | Oct 27, 2026, 10:04 AM UTC
M
Nautilus Biotechnology Reports Third-Quarter 2026 Results
EQUITY | Oct 27, 2026, 10:03 AM UTC
L
Nautilus Biotechnology Q3 EPS USD -0.12
EARNINGS | Oct 27, 2026, 10:02 AM UTC
L
Nautilus Biotechnology Initiated at Buy by Roth Capital
Ratings actions from Benzinga: GMT) Nautilus Biotechnology Price Target Announced at $3.50/Share by Roth CapitalRatings actions from Benzinga
NEWS | Sep 29, 2026, 09:40 AM UTC
L
Nautilus Biotechnology May Offer Up To $300 Million Of Securities - SEC Filing
Nautilus Biotechnology, Inc. NASDAQ:NAUT
REGULATION | Sep 11, 2026, 08:22 PM UTC
L
Nautilus Biotechnology Launches $125 Million ATM Program With TD Cowen; Agent Fee Up to 3%
Nautilus Biotechnology established a new at-the-market (ATM) Sales Agreement with TD Cowen to sell up to $125 million of common stock, while simultaneously terminating its February 28, 2024 ATM agreement with the same co
EQUITY | Sep 11, 2026, 08:14 PM UTC
L
Nautilus Biotechnology initiated at Outperform by Leerink
Nautilus Biotechnology was initiated at Outperform by Leerink Partners.
EQUITY | Sep 09, 2026, 03:30 PM UTC
L
Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms
First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilus is now extending a
EQUITY | Sep 04, 2026, 12:07 PM UTC
L
NAUT - Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms
NAUT - Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms
EQUITY | Sep 04, 2026, 12:01 PM UTC
L
NAUT Nautilus Biotechnology RESULTS: Q2, Q2 Net Income $-14.469M, Q2 EPS $-0.11, Q2 operating expenses $15.938M
NAUT Nautilus Biotechnology RESULTS: Q2, Q2 Net Income $-14.469M, Q2 EPS $-0.11, Q2 operating expenses $15.938M
EARNINGS | Jul 28, 2026, 12:03 PM UTC
H
Top 3 Health Care Stocks That May Rocket Higher In July
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength o
EARNINGS | Jul 06, 2026, 10:11 AM UTC